AstraZeneca: asthma drug shows positive results in trial.
(CercleFinance.com) - AstraZeneca said an experimental asthma drug that it has developed in collaboration with Amgen showed positive results in an intermediate trial, which sent the shares up slightly in London this morning.
Amgen and AstraZeneca said the drug, named tezepelumab, showed a significant reduction in annual exacerbation rate in patients with severe asthma compared with placebo.
The Phase 2b trial achieved its primary efficacy endpoint, showing asthma exacerbation rate reductions of 61%, 71% and 66% in the tezepelumab arms receiving either 70 mg or 210 mg every four weeks or 280 mg every two weeks, respectively.
Tezepelumab is a novel monoclonal antibody being developed by MedImmune, AstraZeneca's global biologics research and development arm, in collaboration with Amgen.
About 315 million people have asthma worldwide, of whom up to 10% have severe asthma.
This morning the drugmaker also announced positive top-line results from the Phase III trial for Duaklir, which met its primary endpoints, demonstrating a statistically-significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
AstraZeneca shares are currently up 0.6% at 4,603 pence after these results, compared to a 0.1% drop in the FTSE 100 index.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Amgen and AstraZeneca said the drug, named tezepelumab, showed a significant reduction in annual exacerbation rate in patients with severe asthma compared with placebo.
The Phase 2b trial achieved its primary efficacy endpoint, showing asthma exacerbation rate reductions of 61%, 71% and 66% in the tezepelumab arms receiving either 70 mg or 210 mg every four weeks or 280 mg every two weeks, respectively.
Tezepelumab is a novel monoclonal antibody being developed by MedImmune, AstraZeneca's global biologics research and development arm, in collaboration with Amgen.
About 315 million people have asthma worldwide, of whom up to 10% have severe asthma.
This morning the drugmaker also announced positive top-line results from the Phase III trial for Duaklir, which met its primary endpoints, demonstrating a statistically-significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
AstraZeneca shares are currently up 0.6% at 4,603 pence after these results, compared to a 0.1% drop in the FTSE 100 index.
Copyright (c) 2017 CercleFinance.com. All rights reserved.